Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Baylor-Sammons Cancer Center, Dallas, Texas, United States



Survival: 14.5 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs: Taxotere
Xeloda
Country: United States
   
City/State/Province: Dallas, Texas
   
Hospital: Baylor-Sammons Cancer Center
   
Journal: Link
   
Date: 6/2002

Description:
Patients: This Phase III study involved 511 women with metastatic breast cancer or breast cancer that was unresectable and locally advanced. Patients were divided into two groups: Group A contained 255 patients, and Group B contained 256 patients.

Treatment: The treatment for patients in group A consisted of two chemotherapy drugs – docetaxel (taxotere) and capecitabine (xeloda). The treatment for patients in group B consisted of only docetaxel.

Toxicity: In Group A, one patient died of entercolitis which was “probably” related to the treatment. Another patient died of sepsis which was “possibly related” to the treatment. A third patient died of pulmonary edema that was “probably related” to the treatment. And a fourth patient died from hepatic coma that was “possibly” related to the treatment. In addition, grade 3-4 toxicities included: neutropenic fever, stomatitis, diarrhea, nausea, hand-foot syndrome, alopecia, and fatigue/asthenia.

Results: Median survival for patients in Group A was 14.5 months.

Support: This research was supported by F. Hoffman-La Roche. In addition, some of the study’s authors have received monetary compensation (over $2,000/year) from F. Hoffman-La Roche or Aventis, or both. Aventis markets taxotere and Roche markets xeloda.

Correspondence: Joyce O'Shaughnessy, MD

E-mail to a Friend Email Physician More Information